The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action

Kristine J Hare, Tina Vilsbøll, Meena Asmar, Carolyn F Deacon, Filip K Knop, Jens J Holst, Kristine J Hare, Tina Vilsbøll, Meena Asmar, Carolyn F Deacon, Filip K Knop, Jens J Holst

Abstract

Objective: Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic beta- and alpha-cells. Previous studies have focused on the improvements in beta-cell function, while the inhibition of alpha-cell secretion has received less attention. The aim of this research was to quantify the glucagonostatic contribution to the glucose-lowering effect of GLP-1 infusions in patients with type 2 diabetes.

Research design and methods: Ten male patients with well-regulated type 2 diabetes (A1C 6.9 +/- 0.8%, age 56 +/- 10 years, BMI 31 +/- 3 kg/m(2) [means +/- SD]) were subjected to five 120-min glucose clamps at fasting plasma glucose (FPG) levels. On day 1, GLP-1 was infused to stimulate endogenous insulin release and suppress endogenous glucagon. On days 2-5, pancreatic endocrine clamps were performed using somatostatin infusions of somatostatin and/or selective replacement of insulin and glucagon; day 2, GLP-1 plus basal insulin and glucagon (no glucagon suppression or insulin stimulation); day 3, basal insulin only (glucagon deficiency); day 4, basal glucagon and stimulated insulin; and day 5, stimulated insulin. The basal plasma glucagon levels were chosen to simulate portal glucagon levels.

Results: Peptide infusions produced the desired hormone levels. The amount of glucose required to clamp FPG was 24.5 +/- 4.1 (day 1), 0.3 +/- 0.2 (day 2), 10.6 +/- 1.1 (day 3), 11.5 +/- 2.7 (day 4), and 24.5 +/- 2.6 g (day 5) (day 2 was lower than days 3 and 4, which were both similar and lower than days 1 and 5).

Conclusions: We concluded that insulin stimulation (day 4) and glucagon inhibition (day 3) contribute equally to the effect of GLP-1 on glucose turnover in patients with type 2 diabetes, and these changes explain the glucose-lowering effect of GLP-1 (day 5 vs. day 1).

Figures

FIG. 1.
FIG. 1.
Plasma levels of glucose (A), GLP-1 (B), glucagon (C), insulin (D), and C-peptide (E) during day 1 (●), day 2 (▲), day 3 (■), day 4 (△), and day 5 (○). Data shown are means ± SEM. NS indicates P > 0.5.
FIG. 2.
FIG. 2.
Glucose demand (g) for each day: day 1: GLP-1(insulin stimulation, glucagon inhibition); day 2: GLP-1, somatostatin, basal insulin, basal glucagon; day 3: somatostatin, basal insulin; day 4: somatostatin, “stimulated” insulin (mimicking day 1-insulin response), basal glucagon; day 5: somatostatin, “stimulated” insulin (mimicking day 1-insulin response). Data shown are means ± SEM. A: Glucose demands on each day shown in grams infused (g); means ± SEM. B: Glucose demand calculated from each interval of 30 min on each day. Data shown in grams (g); means ± SEM. NS indicates P > 0.5, *P < 0.5, ***P < 0.001.

References

    1. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA: Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I (7–36) amide in type I diabetic patients. Diabetes Care 1996;19:580–586
    1. de Heer J, Rasmussen C, Coy DH, Holst JJ: Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 2008;51:2263–2270
    1. Hvidberg A, Nielsen MT, Hilsted J, Orskov C, Holst JJ: Effect of glucagon-like peptide-1 (proglucagon 78–107 amide) on hepatic glucose production in healthy man. Metabolism 1994;43:104–108
    1. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741–744
    1. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ: Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001;86:3717–3723
    1. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA: Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000;85:4053–4059
    1. Shah P, Basu A, Basu R, Rizza R: Impact of lack of suppression of glucagon on glucose tolerance in humans. Am J Physiol 1999;277:E283–E290
    1. Ahrén B, Larsson H, Holst JJ: Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997;82:473–478
    1. Vilsboll T, Krarup T, Madsbad S, Holst JJ: Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 2002;45:1111–1119
    1. Hare KJ, Knop FK, Asmar M, Madsbad S, Deacon CF, Holst JJ, Vilsbøll T: Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus. J Clin Endocrinol Metab 2009;94:4679–4687
    1. Orskov L, Holst JJ, Møller J, Orskov C, Møller N, Alberti KG, Schmitz O: GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia 1996;39:1227–1232
    1. De Feo P, Perriello G, Torlone E, Ventura MM, Santeusanio F, Brunetti P, Gerich JE, Bolli GB: Demonstration of a role for growth hormone in glucose counterregulation. Am J Physiol 1989;256:E835–E843
    1. Nauck MA, Blietz RW, Qualmann C: Comparison of hyperinsulinaemic clamp experiments using venous, ‘arterialized’ venous or capillary euglycaemia. Clin Physiol 1996;16:589–602
    1. Bablok W, Passing H, Bender R, Schneider B: A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. J Clin Chem Clin Biochem 1988;26:783–790
    1. Holst JJ: Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33–69) of glicentin. Biochem J 1982;207:381–388
    1. Orskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ: Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994;43:535–539
    1. Holst JJ, Burcharth F, Kühl C: Pancreatic glucoregulatory hormones in cirrhosis of the liver: portal vein concentrations during intravenous glucose tolerance test and in response to a meal. Diabete Metab 1980;6:117–127
    1. Alford FP, Bloom SR, Nabarro JD, Hall R, Besser GM, Coy DH, Kastin AJ, Schally AV: Glucagon control of fasting glucose in man. Lancet 1974;2:974–977
    1. Jiang G, Zhang BB: Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab 2003;284:E671–E678
    1. Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A: Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004;89:2078–2084
    1. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde LLEAD-6 Study Group Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39–47
    1. Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O: One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004;53:1187–1194
    1. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter LDURATION-1 Study Group Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372:1240–1250
    1. Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824–830
    1. Knop FK, Vilsbøll T, Madsbad S, Holst JJ, Krarup T: Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia 2007;50:797–805
    1. Müller WA, Faloona GR, Aguilar-Parada E, Unger RH: Abnormal alpha-cell function in diabetes: response to carbohydrate and protein ingestion. N Engl J Med 1970;283:109–115
    1. Toft-Nielsen MB, Madsbad S, Holst JJ: Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 1999;22:1137–1143
    1. Unger RH, Orci L: The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1975;1:14–16
    1. Vilsbøll T, Krarup T, Madsbad S, Holst JJ: Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 2003;114:115–121

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir